Fulcrum Therapeutics, Inc. Income Statement

Income Statement Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 8.82M19.16M6.34M2.81M80.00M
Gross Profit 8.82M19.16M6.34M2.81M80.00M
Operating items
Research & Development 71.07M59.04M69.70M76.78M71.80M63.39M
Selling, General & Administrative 13.14M21.39M30.52M41.69M41.67M36.45M
Restructuring Costs 0.43M2.06M
Operating Expenses 84.22M80.43M100.22M118.90M113.47M101.90M
Operating Income -84.22M-71.61M-81.05M-112.56M-110.66M-21.90M
EBIT -84.22M-71.61M-81.05M-112.56M-110.66M-21.90M
Non-operating items
Interest & Investment Income 1.51M0.79M0.21M2.69M13.33M12.17M
Other Non Operating Income 0.03M
Net income details
EBT -82.71M-70.82M-80.85M-109.87M-97.33M-9.72M
Profit After Tax -82.68M-70.82M-80.85M-109.87M-97.33M-9.72M
Income from Continuing Operations -82.71M-70.82M-80.85M-109.87M-97.33M-9.72M
Consolidated Net Income -82.71M-70.82M-80.85M-109.87M-97.33M-9.72M
Income towards Parent Company -82.71M-70.82M-80.85M-109.87M-97.33M-9.72M
Preferred Dividend Payments 7.13M
Net Income towards Common Stockholders -89.81M-70.82M-80.85M-109.87M-97.33M-9.72M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 23.34M23.34M27.46M40.55M52.05M61.82M53.94M
Shares Outstanding (Diluted Average) 0.03M0.04M0.04M0.06M0.06M
EBITDA -84.22M-70.82M-81.24M-110.27M-96.67M-9.46M